News
Monoclonal antibody “cocktail” blocks COVID-19 variants: study
Mar. 5, 2021—Mar. 4, 2021, 11:19 AM by Bill Snyder A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine. That was one of the findings reported by a...
Chikungunya antibody identified by Crowe lab moves forward
Mar. 4, 2021—Mar. 4, 2021, 8:54 AM by Bill Snyder Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center. This is the second monoclonal antibody against the debilitating tropical viral infection isolated in the...
Steve Townsend wins Sloan Research Fellowship
Mar. 3, 2021—by Ann Marie Deer Owens Feb. 16, 2021, 9:22 AM Assistant Professor of Chemistry Steven Townsend (Susan Urmy/Vanderbilt) Assistant Professor of Chemistry Steven D. Townsend, PhD’10, has been awarded a 2021 Sloan Research Fellowship, one of the highest honors for young scientists who have the potential to revolutionize their fields of study. Townsend, who previously...
Bordenstein elected to American Academy of Microbiology
Mar. 3, 2021—by Ann Marie Deer Owens Mar. 2, 2021, 5:30 PM Seth Bordenstein (Vanderbilt University) Seth Bordenstein, Centennial Professor of Biological Sciences, has been elected to fellowship in the American Academy of Microbiology, the honorific leadership group within one of the largest life science societies in the world. “I am honored to join the leadership group...
Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Feb. 26, 2021—by Marissa Shapiro Feb. 25, 2021, 8:00 AM A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes. Jerod Denton Craig Lindsley Leading the collaboration are WCNDD director Craig Lindsley, who holds the William K....
Despite limitations of pandemic, research continues in Basic Sciences
Feb. 24, 2021—Feb. 24, 2021, 8:00 AM By Jenna Somers Vanderbilt researchers are prolific and resolute in their pursuit of transformative research and innovation. During the Research Ramp-up process, more than 3,000 Vanderbilt research personnel have returned to in-person research activities, while many others have continued remotely through perseverance and ingenuity. On campus and at home, they...
Christov & Westover Receive Research Staff Awards
Feb. 22, 2021—Research Staff Awards honor those who help drive engines of discovery Feb. 18, 2021, 9:57 AM by Bill Snyder Laboratory and administrative personnel at Vanderbilt University Medical Center were honored last week for research excellence during the 17th annual Research Staff Awards, held virtually this year because of the pandemic. “We’re really honoring the...
Genetic clues in eye birth defect
Feb. 18, 2021—Feb. 18, 2021, 11:00 AM by Leigh MacMillan Uveal coloboma can affect the iris — the colored part of the eye — giving it a keyhole appearance. (iStock) Uveal coloboma — a birth defect that causes a malformation of the eye — accounts for up to 10% of childhood blindness. Coloboma results from a defective...
Dean’s Faculty Fellows program recognizes Neuert, Ren
Feb. 17, 2021—By Lorena Infante Lara, February 15, 2021 Assistant Professor of Biochemistry Yi Ren and Assistant Professor of Molecular Physiology and Biophysics Gregor Neuert have been recognized as School of Medicine Basic Sciences Dean’s Faculty Fellows. Established in 2020, the Dean’s Faculty Fellows program in Basic Sciences is designed to recognize the efforts of faculty in...
SARS-CoV-2 protein blocks an essential step in host gene expression, new discovery finds
Feb. 17, 2021—by Marissa Shapiro Feb. 17, 2021, 9:00 AM Vanderbilt biochemist Yi Ren is part of a team that has identified a new behavior of a SARS-CoV-2 protein and discovered that interfering with its function can block virus replication in host cells. This opens up the potential for new therapeutic targets for COVID-19. Yi Ren (Vanderbilt...